1002330-78-0

Basic information

• Product Name: (2R)-3-bromo-N-(3-chloro-4-cyanophenyl)-2-hydroxy-2-methylpropanamide
• Synonyms: (2R)-3-bromo-N-(3-chloro-4-cyanophenyl)-2-hydroxy-2-methylpropanamide
• CAS NO: 1002330-78-0
• Molecular Weight: 317.57
• Mol File: 1002330-78-0.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: (2R)-3-bromo-N-(3-chloro-4-cyanophenyl)-2-hydroxy-2-methylpropanamide(CAS DataBase Reference)
• NIST Chemistry Reference: (2R)-3-bromo-N-(3-chloro-4-cyanophenyl)-2-hydroxy-2-methylpropanamide(1002330-78-0)
• EPA Substance Registry System: (2R)-3-bromo-N-(3-chloro-4-cyanophenyl)-2-hydroxy-2-methylpropanamide(1002330-78-0)

Safety Data

• Hazardous Substances Data: 1002330-78-0(Hazardous Substances Data)

Upstream product

• 20925-27-3 4-amino-2-chlorobenzonitrile 
• 1010396-30-1 (R)-3-bromo-2-hydroxy-2-methylpropanoyl chloride 
• 261904-39-6 (2R)-3-bromo-2-hydroxy-2-methylpropanoic acid 
• 81026-68-8 (R)-3-bromo-2-hydroxy-2-methylpropanoic acid 

Downstream Products

• 1010729-04-0 (S)-N-(3-chloro-4-cyanophenyl)-2-methyloxirane-2-carboxamide 
• 928122-40-1 ((S)-N-(3-chloro-4-cyanophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide) 
• 1202044-23-2 (S)-N-(3-chloro-4-cyanophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide-d4 

Relevant articles and documents

Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer

We report herein the design, synthesis, and pharmacological characterization of a library of novel aryl pyrazol-1-yl-propanamides as selective androgen receptor degraders (SARDs) and pan-Antagonists that exert broad-scope AR antagonism. Pharmacological ev

SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF

This invention is directed to selective androgen receptor degrader (SARD) compounds including heterocyclic rings and pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedys disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.

Aromatic amide compound and preparation method and application thereof

The invention relates to an aromatic amide compound as shown in general formula I, a preparation method of the aromatic amide compound, a pharmaceutical composition containing the compound as shown ingeneral formula I, a pharmaceutic preparation containin